KR101566042B1 - 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체 - Google Patents

진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체 Download PDF

Info

Publication number
KR101566042B1
KR101566042B1 KR1020107008594A KR20107008594A KR101566042B1 KR 101566042 B1 KR101566042 B1 KR 101566042B1 KR 1020107008594 A KR1020107008594 A KR 1020107008594A KR 20107008594 A KR20107008594 A KR 20107008594A KR 101566042 B1 KR101566042 B1 KR 101566042B1
Authority
KR
South Korea
Prior art keywords
alkyl
mmol
pyridin
formula
yloxy
Prior art date
Application number
KR1020107008594A
Other languages
English (en)
Korean (ko)
Other versions
KR20100080809A (ko
Inventor
토마스 다니엘 아이처
스티븐 아멘 보이드
마크 조셉 시카렐리
케빈 로날드 콘드로스키
제이 브래드포드 펠
존 피. 피셔
인드라니 더블유. 구나와르다나
로날드 제이 힌클린
아제이 싱
티모시 엠. 터너
엘리 엠. 왈라스
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20100080809A publication Critical patent/KR20100080809A/ko
Application granted granted Critical
Publication of KR101566042B1 publication Critical patent/KR101566042B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
KR1020107008594A 2007-09-21 2008-09-15 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체 KR101566042B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21
US60/974,225 2007-09-21

Publications (2)

Publication Number Publication Date
KR20100080809A KR20100080809A (ko) 2010-07-12
KR101566042B1 true KR101566042B1 (ko) 2015-11-04

Family

ID=40250949

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008594A KR101566042B1 (ko) 2007-09-21 2008-09-15 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체

Country Status (29)

Country Link
US (3) US8212045B2 (uk)
EP (4) EP2209778B1 (uk)
JP (1) JP5722037B2 (uk)
KR (1) KR101566042B1 (uk)
CN (1) CN101868459B (uk)
AR (1) AR068628A1 (uk)
AU (1) AU2008305294B2 (uk)
BR (1) BRPI0816881A2 (uk)
CA (1) CA2699718C (uk)
CO (1) CO6270223A2 (uk)
CR (2) CR11383A (uk)
DK (1) DK2209778T3 (uk)
EA (1) EA019104B1 (uk)
ES (2) ES2569734T3 (uk)
HK (2) HK1145498A1 (uk)
HR (1) HRP20120814T1 (uk)
IL (1) IL204264A (uk)
MA (1) MA31779B1 (uk)
MX (1) MX2010002772A (uk)
MY (1) MY180558A (uk)
NZ (1) NZ583538A (uk)
PL (1) PL2209778T3 (uk)
PT (1) PT2209778E (uk)
SI (1) SI2209778T1 (uk)
TN (1) TN2010000100A1 (uk)
TW (1) TWI423799B (uk)
UA (1) UA101166C2 (uk)
WO (1) WO2009042435A1 (uk)
ZA (2) ZA201002206B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2131656A4 (en) * 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX2013002208A (es) 2010-08-23 2013-05-30 Amgen Inc Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
JP2014510145A (ja) 2011-04-05 2014-04-24 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用ベンゾジオキセピンおよびベンゾジオキシン化合物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
CA2877026A1 (en) 2012-05-18 2013-11-21 Amgen Inc. Method for the preparation of thiadiazoles
CA2890852A1 (en) * 2012-11-09 2014-05-15 Array Biopharma Inc. Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019089478A1 (en) 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
AU2019278017A1 (en) * 2018-05-31 2021-01-21 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition and formulation containing glucokinase activator and alpha-glucosidase inhibitor, preparation methods therefor and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
WO1993024442A1 (en) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
CA2193725A1 (en) 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
EP1178973B1 (en) 1999-05-21 2005-12-21 Biovitrum Ab Pyrazinyl-piperazine- compounds, their use and preparation
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 １，２，４−チアジアゾール誘導体の合成法
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
AU2001280009A1 (en) 2000-08-31 2002-03-13 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
AU2002213466A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
EP1341773A2 (en) 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
AU2002346053B2 (en) * 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
CN102151273B (zh) 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物
ATE433973T1 (de) 2002-03-15 2009-07-15 Vertex Pharma Azolylaminoazine als inhibitoren von proteinkinasen
EP1485100B1 (en) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AU2003227360A1 (en) * 2002-04-25 2003-11-10 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
TW200812986A (en) 2002-08-09 2008-03-16 Nps Pharma Inc New compounds
AU2003272324A1 (en) 2002-09-10 2004-04-30 Scios Inc. INHIBITORS OF TFGBeta
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
EP1603878B1 (en) 2003-02-10 2013-01-02 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
JP2006522125A (ja) 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CA2537141A1 (en) 2003-09-02 2005-03-10 Merck And Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP2007530631A (ja) 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
WO2005121126A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
ATE499370T1 (de) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
EP1917259B1 (en) 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
KR20080040046A (ko) * 2005-08-31 2008-05-07 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
SG166827A1 (en) 2005-11-03 2010-12-29 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
WO2007058482A1 (en) 2005-11-16 2007-05-24 Lg Life Sciences, Ltd. Novel inhibitors of protein kinase
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
ES2378704T3 (es) 2006-01-27 2012-04-17 Array Biopharma, Inc. Activadores de la glucocinasa
MY148985A (en) 2006-03-24 2013-06-28 Array Biopharma Inc 2-aminopyridine analogs as glucokinase activators
DE602007009085D1 (de) 2006-05-12 2010-10-21 Ab Science Neues verfahren zur synthese von 2-aminooxazolverbindungen
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
JP5450108B2 (ja) * 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
WO2008124083A2 (en) 2007-04-05 2008-10-16 Amgen Inc. Aurora kinase modulators and method of use
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
UY31281A1 (es) 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
CA2699718C (en) 2007-09-21 2014-05-27 Array Biopharma Inc. Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
PL2195312T3 (pl) 2007-10-09 2013-04-30 Merck Patent Gmbh Pochodne pirydynowe użyteczne jako aktywatory glukokinazowe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators

Also Published As

Publication number Publication date
EP2209778A1 (en) 2010-07-28
EP2209778B1 (en) 2012-08-29
TN2010000100A1 (en) 2011-09-26
US20150057448A1 (en) 2015-02-26
WO2009042435A1 (en) 2009-04-02
CN101868459B (zh) 2013-12-18
EP2573087A1 (en) 2013-03-27
US8212045B2 (en) 2012-07-03
IL204264A (en) 2015-06-30
PL2209778T3 (pl) 2013-02-28
HK1197821A1 (zh) 2015-02-18
EP3078662A1 (en) 2016-10-12
AU2008305294A1 (en) 2009-04-02
SI2209778T1 (sl) 2012-12-31
KR20100080809A (ko) 2010-07-12
MA31779B1 (fr) 2010-10-01
AU2008305294B2 (en) 2012-11-29
CA2699718C (en) 2014-05-27
MY180558A (en) 2020-12-02
TWI423799B (zh) 2014-01-21
CN101868459A (zh) 2010-10-20
CO6270223A2 (es) 2011-04-20
US9079890B2 (en) 2015-07-14
MX2010002772A (es) 2010-03-31
JP5722037B2 (ja) 2015-05-20
ES2393824T3 (es) 2012-12-28
WO2009042435A8 (en) 2009-10-08
US20100204240A1 (en) 2010-08-12
US20120277242A1 (en) 2012-11-01
BRPI0816881A2 (pt) 2015-03-17
AR068628A1 (es) 2009-11-25
CR11383A (es) 2010-08-13
US8853409B2 (en) 2014-10-07
ZA201102350B (en) 2012-09-26
UA101166C2 (uk) 2013-03-11
ZA201002206B (en) 2011-06-29
CA2699718A1 (en) 2009-04-02
DK2209778T3 (da) 2012-09-17
ES2569734T3 (es) 2016-05-12
HRP20120814T1 (hr) 2012-11-30
TW200914007A (en) 2009-04-01
PT2209778E (pt) 2012-12-06
EP2727910A1 (en) 2014-05-07
EA201000515A1 (ru) 2010-10-29
HK1145498A1 (en) 2011-04-21
EP2727910B1 (en) 2016-03-16
NZ583538A (en) 2012-06-29
CR20150131A (es) 2015-04-30
JP2010540443A (ja) 2010-12-24
EA019104B1 (ru) 2014-01-30

Similar Documents

Publication Publication Date Title
KR101566042B1 (ko) 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-２-일-아미노-１,２,４-티아디아졸 유도체
JP5450108B2 (ja) グルコキナーゼ活性化剤としての２−アミノピリジン類似体
JP2010527911A5 (uk)
JP4400563B2 (ja) 新規２−ピリジンカルボキサミド誘導体
EP2858983B1 (en) Tnf-alpha modulating benzimidazoles
US11464775B2 (en) Pyruvate kinase modulators and use thereof
US8431713B2 (en) 2-aminopyridine derivatives as glucokinase activators
TWI819577B (zh) Glp-1r調節化合物
US20070179156A1 (en) Pyridones useful as inhibitors of kinases
JP2010518014A (ja) キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US7786120B2 (en) Pyridones useful as inhibitors of kinases
US20170158704A1 (en) Pyrimidinone derivative having autotaxin-inhibitory activity
US8673922B2 (en) Azaindazole compounds
RU2797518C2 (ru) Модуляторы пируваткиназы и их применение

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee